Abeona Therapeutics (ABEO)
(Delayed Data from NSDQ)
$4.95 USD
-0.03 (-0.60%)
Updated Aug 14, 2024 03:59 PM ET
After-Market: $4.94 -0.01 (-0.20%) 5:24 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
Abeona Therapeutics Inc. [ABEO]
Reports for Purchase
Showing records 41 - 60 ( 89 total )
Company: Abeona Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Authorization Granted for European Enrollment Initiation in Sanfilippo Syndrome Type B; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Abeona Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
2Q 2018 Financial Results Reported; Multiple Clinical Development Milestones Ahead; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Abeona Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Chief Commercial Officer Appointed; Chief Operating Officer Steps Down; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Abeona Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Commercial Gene and Cell Therapy Manufacturing Facility Opened; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Abeona Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Additional Data Presented on ABO-102 and EB-101; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Abeona Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
1Q 2018 Financial Results Reported; Cleveland Facility Opening Near Term; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Abeona Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
ABO-102 Receives RMAT Designation; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Abeona Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Orphan Drug Designation Received in Europe for ABO-202 in Batten Disease; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Abeona Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Recent M-A Activity Underscores Rare Disease Strategic Importance; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Abeona Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
New Chief Executive Officer Appointed; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Abeona Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
4Q and FY2017 Financial Results Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Abeona Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
ABO-102 Clinical Data Update at WORLDSymposium; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Abeona Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Initial Safety and Biopotency Reported for ABO-101; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Abeona Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Gene Therapy Preclinical Toxicity Observations Appear Non-Relevant; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Abeona Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Second Sanfilippo Syndrome Candidate Advancing; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Abeona Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
3Q17 Financial Results Reported; Multiple Programs Advancing; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Abeona Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
R-D Day Showcases Pipeline Value; Reiterate Buy and Raising Price Target to $30
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Abeona Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
ABO-102 Top-Line Data Presented; Analyst Day on Deck; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Abeona Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Competitor Failure in Epidermolysis Bullosa (EB) Underscores Critical Need; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: Abeona Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Breakthrough Therapy Status Granted for EB-101; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R